A decade of innovation, a decade to come

To the participants in China’s Biopharmaceutical Innovation

Over the last decade, Mainland China has transformed into a global leader in biopharmaceutical innovation, driven by ambitious policies, substantial investments in research and development, and a reformed regulatory landscape. Key initiatives like ‘Made in China 2025’ and ‘Healthy China 2030’ have established a supportive ecosystem that nurtures high-quality innovation, accelerating the approval and accessibility of life-changing therapies.
With an impressive 23% contribution to the global pipeline of innovative drugs, Mainland China’s biopharmaceutical industry is scaling, facilitating advancements in healthcare accessibility and affordability through multi-level medical security systems and streamlined drug approval pathways. This report from Clarivate presents an in-depth analysis of these groundbreaking shifts and sets the stage for the decade to come.

Read the report to find out:

• How Mainland China’s policies and reforms—such as the priority review pathway—are expediting the approval process for innovative drugs.
• The role of strategic hubs like the Yangtze River Delta and Guangdong-Hong Kong-Macao Greater Bay Area in fostering biopharmaceutical innovation clusters.
• Key metrics on Mainland China’s growing impact on the global biopharmaceutical pipeline, now ranking third in launching new innovative drugs.
• Insights into the government’s multi-level medical security initiatives, which enhance accessibility and affordability for high-value drugs.
• The rise of advanced research areas like gene editing, synthetic biology, and immunotherapies, positioning Mainland China as a leader in next-generation therapies.
• Trends in international collaborations and the expanding role of commercial health insurance to support innovative treatments.